



Kenneth F. Baum, M.D.

Partner / Santa Monica

P: 310-576-6900

kbaum@goldmanismail.com

"Ken Baum is widely regarded as one of the premier trial lawyers in the product liability and mass tort space, and his dual training as both a lawyer and a physician is a significant differentiator. As a JD-MD, Ken brings an unmatched level of medical and scientific fluency to pharmaceutical and medical device litigation, allowing him to engage deeply with clinical data, regulatory records, and complex causation issues." – *The Legal 500*

"Ken is the best science lawyer in the country. He works incredibly hard to stay in front of every issue." – *Chambers USA* (ranked 2018-2026)

Ken brings a highly specialized skill set to defending claims brought against drug and medical device manufacturers. A graduate of both Yale Law School and the Yale University School of Medicine, Ken is widely regarded by clients and his peers as one of the nation's leading practitioners in the products liability arena. Clients reporting to *The Legal 500* repeatedly single out Ken as a "very hardworking, very skilled trial lawyer," and a key practitioner in products liability and mass tort defense.

With a unique ability to synthesize and convey complex scientific and medical issues, Ken leads national science and expert teams in high-profile products liability litigations, including Vioxx® (Merck), Sprint Fidelis® (Medtronic), Seroquel® (AstraZeneca), gadolinium contrast dye (Bayer), Fosamax® (Merck), Mirena® (Bayer), Zostavax® (Merck), and GLP-1 receptor agonist litigation (Eli Lilly). Clients turn to Ken to depose key expert and treating physician witnesses, and his depositions have repeatedly led to litigation-ending *Daubert* rulings. Ken also is a pillar of bellwether trial teams, crafting case strategies and witness examinations that have led to numerous trial victories and, ultimately, the dismissal of thousands of cases nationwide.

Representative Litigation

GLP-1 Receptor Agonists Litigation

Leader of national science and expert team for Eli Lilly in litigation concerning its diabetes and weight management drugs Mounjaro®, Zepbound®, and Trulicity®.

Fosamax Litigation

National science and expert team member and trial counsel for Merck & Co., Inc. in litigation concerning Fosamax®, a prescription drug used for the treatment and prevention of osteoporosis and other bone disorders.

Mirena IUD Litigation

Leader of national science and expert team for Bayer HealthCare Pharmaceuticals Inc. in litigation concerning the Mirena® intrauterine device.

Zostavax Litigation

Counsel and national science and expert team member for Merck & Co., Inc. in litigation concerning Merck’s shingles vaccine, Zostavax®.

PFAS Environmental Litigation

National counsel for chemical manufacturer in thousands of environmental and products liability claims in state and federal courts nationwide brought by individuals, municipalities, and states alleging groundwater contamination and personal injury as individual claims, consolidated proceedings, and class actions.

Vioxx Litigation

National science and expert team member and trial counsel for Merck & Co., Inc. in litigation concerning Vioxx®, a prescription anti-inflammatory medication.

Gadolinium Contrast Dye Litigation

Counsel and leader of national science and expert team for Bayer HealthCare Pharmaceuticals Inc. in litigation concerning Bayer’s gadolinium-based contrast agents used in magnetic resonance imaging.

Sprint Fidelis Litigation

National science and expert team member for Medtronic in litigation concerning Medtronic’s Sprint Fidelis® heart defibrillator leads.

Seroquel Litigation

Counsel and national science and expert team member for AstraZeneca Pharmaceuticals in litigation concerning the prescription drug, Seroquel®, which is used to treat certain mental health disorders.

Baycol Litigation

Counsel and national science and expert team member for Bayer Corp. in litigation concerning Baycol®, a prescription cholesterol-reducing medication.

Hormone Replacement Therapy Litigation

National science and expert team member for Wyeth, Inc. in litigation concerning the hormone replacement therapy prescription drugs Premarin® and Prempro®.

Private Practice

Partner, Goldman Ismail Tomaselli Brennan & Baum LLP

Partner, Bartlit Beck Herman Palenchar & Scott LLP

Associate, Bartlit Beck Herman Palenchar & Scott LLP

Associate, Wiggin and Dana LLP

Education

Yale Law School (J.D.)

- Founder and Director, Yale Health Law Society
- Editor, *Yale Journal of Health Policy, Law & Ethics*

Yale University School of Medicine (M.D.)

University of California at Berkeley (B.A., Psychology)

- Highest Academic Distinction
- Junior *Phi Beta Kappa*

Publications

Ken Baum & Julie Cantor, *Doctors Can Ease Suffering, Even in Executions*, New York Times (2014)

Ken Baum, Jennifer Greenblatt & Julie Cantor, [Assessing the Post-Riegel Landscape: The Effect of Sales Representatives' Actions on Preemption Analysis](#), Drug, Device & Biotechnology IADC Committee Newsletter (2014)

Now on PBS: When Law and Ethics Collide – Why Physicians Participate in Executions (TV broadcast, July 14, 2006)

Talk of the Nation: Medical Ethics and Capital Punishment (NPR radio broadcast, Feb. 23, 2006)

Ken Baum, *Independent Medical Examinations: An Expanding Source of Physician Liability*, Annals of Internal Medicine 2005; 142:974-78

Julie Cantor & Ken Baum, *The Limits of Conscientious Objection—May Pharmacists Refuse to Fill Prescriptions for Emergency Contraception?*, New England Journal of Medicine 2004; 351:2008-12

Kenneth Baum, *"To Comfort Always": Physician Participation in Executions*, 5 N.Y.U. J. Legis. & Pub. Pol'y 47 (2002)

Kenneth F. Baum, *Golden Eggs: Towards the Rational Regulation of Oocyte Donation*, 2001 BYU L. Rev. 107 (2001)

Of Note

Named a Leading Life Sciences Lawyer by <i>LMG Life Sciences</i> (2021-2022)	Named Practice Area Star by <i>LMG Life Sciences</i> for Product Liability (2020-2026)
Ranked by <i>Chambers USA</i> as a Leading Individual in Nationwide Product Liability & Mass Torts (2018-2026)	Profiled in <i>The National Law Journal's</i> Special Report, <i>Winning Litigators: High Stakes, Significant Victories</i> (2016)
Designated as a Leading Partner by <i>The Legal 500</i> in US Products Liability, Mass Tort, and Class Action – Defense: Pharmaceuticals and Medical Devices (2023-2026)	Mentioned by <i>The Legal 500</i> for products liability and mass tort defense work (2010, 2012-2014)
Recognized in <i>Who's Who Legal: Thought Leaders Product Liability Defense Lawyers USA</i> (2022-2024)	Recognized in <i>Lexology Index: Thought Leaders Product Liability Defense Lawyers USA</i> (2024-2027)
Recognized in <i>Lexology Index: Thought Leaders Product Regulation & Liability</i> (2025-2026)	Selected by <i>Lawdragon</i> as among the "all-star litigators" "who excel at representing principally corporations and other organizations" in complex litigation, especially product liability, in the 500 Leading Litigators in America guide (2022-2026)

News

Goldman Ismail and Partners Earn Top-Tier Rankings in Legal 500 United States 2026	Goldman Ismail and Partners Earn Top Rankings in the Chambers and Partners 2026 USA Guide
19 Goldman Ismail Partners Named to Lawdragon's List of 500 Leading Litigators in America	Goldman Ismail and Partners Earn Highest 2025 Rankings in The Legal 500

[Goldman Ismail and Partners Earn Top Rankings in 2025 Chambers and Partners](#)

[Goldman Ismail 2024 Chambers and Partners Rankings](#)

[Goldman Ismail Tops 2023 Chambers and Partners Rankings](#)

[Goldman Ismail Tops 2022 Chambers and Partners Rankings](#)

[Second Circuit Court of Appeals Affirms Bayer's Summary Judgment Win in the Mirena I/H MDL](#)

[Goldman Ismail Tops 2020 Chambers and Partners Rankings](#)

[Bayer Wins Dismissal of All Cases in the Mirena I/H MDL](#)

[Goldman Ismail Defeats Plaintiffs' Attempt to Form MDL in Gadolinium Retention Contrast Dye Litigation](#)

[Goldman Ismail Tops 2018 Chambers and Partners Rankings](#)

[Law360 Picks Mirena IUD Products Liability Litigation MDL Ruling as One of Year's Most Significant](#)

[Federal Judge Dismisses All 1225 Cases in Mirena Multidistrict Litigation](#)

[Landmark Daubert Victory for Goldman Ismail—Federal Judge Excludes Plaintiffs' Experts](#)

[Goldman Ismail Lawyers Recognized for Excellence by Chambers and The Legal 500 in 2014](#)

[Goldman Ismail Recognized for Excellence by Chambers USA 2013 and The Legal 500 2013](#)

[Goldman Ismail Wins Complete Defense Verdict for Merck in Bellwether Fosamax Trial](#)

[Goldman Ismail 2024 Legal 500 Rankings](#)

[Goldman Ismail Tops 2023 Legal 500 Rankings](#)

[Goldman Ismail and Partners Receive Top Rankings in LMG Life Sciences 2022](#)

[Goldman Ismail Tops 2021 Chambers and Partners Rankings](#)

[Goldman Ismail Named Product Liability Firm of the Year for 2020 by LMG Life Sciences and Receives Top Rankings](#)

[Bayer Wins Daubert Ruling Excluding Plaintiffs' Expert Witnesses in the Gadolinium Retention Contrast Dye Litigation](#)

[Goldman Ismail Tops 2019 Chambers and Partners Rankings](#)

[Bayer Wins Daubert Ruling Excluding All Plaintiffs' Expert Witnesses in the Mirena I/H MDL](#)

[Second Circuit Affirms Orders Dismissing All 1200+ Cases in Mirena Perforation MDL](#)

[Tarek Ismail and Ken Baum Named Winning Litigators in The National Law Journal Special Report](#)

[Second Circuit Affirms Mirena MDL Dismissals](#)

[Goldman Ismail wins Fosamax Bellwether trial in California for Merck](#)

[Drug, Device and Biotechnology Committee Newsletter, "Assessing the Post-Riegel Landscape: The Effect of Sales Representatives' Actions on Preemption Analyses"](#)

[The Legal 500 2012 Ranks Goldman Ismail as Top Firm for Products Liability Litigation](#)

[Goldman Ismail Obtains Complete Defense Verdict for Merck in Vioxx Case Brought by LA Attorney General](#)

Bar & Court Admission

State of California

State of Connecticut (inactive)
